LYPRO Biosciences

LYPRO Biosciences is a biopharmaceutical company specializing in the development of a proprietary drug delivery platform known as Nano-Lipoprotein Particles (NLPs). These NLPs are synthetic analogs of naturally occurring high-density lipoproteins (HDL) designed to encapsulate and transport hydrophobic drugs, which often face solubility and toxicity challenges. The platform specifically targets the Scavenger Receptor B Type I (SR-BI), which is highly expressed on various cancer cells, allowing for selective uptake of the therapeutic payload. LYPRO's pipeline primarily focuses on enhancing the delivery of established oncology agents and exploring applications in infectious diseases. The company's goal is to improve the therapeutic index of potent drugs by increasing precision and reducing systemic side effects.